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Abstract ADAMs are membrane-anchored glycoproteins con-
taining a disintegrin and metalloprotease domain that have
important roles in fertilization, development, and diseases such as
Alzheimer’s dementia. Here we present the first evidence for
catalytic activity of ADAM28, a protein that is highly expressed
in the epididymis and lymphocytes. Recombinant ADAM28
cleaves myelin basic protein at two sites. The catalytic activity
of ADAM28 is not sensitive to tissue inhibitors of metallopro-
teases 1 and 2, but can be abolished by a mutation in the catalytic
site. Catalytically active ADAM28 will be valuable for further
studies of its role in sperm maturation and lymphocyte
function. ß 2001 Published by Elsevier Science B.V. on behalf
of the Federation of European Biochemical Societies.
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1. Introduction
ADAMs are a family of membrane-anchored glycoproteins
with roles in fertilization, myogenesis, neurogenesis, diseases
such as Alzheimer’s disease, and in a process termed protein
ectodomain shedding [1^3]. A typical ADAM consists of an
amino-terminal signal sequence, followed by a pro-domain, a
metalloprotease domain, a disintegrin domain and cysteine-
rich region, an EGF repeat, transmembrane domain and cyto-
plasmic tail. Currently, 24 ADAMs are known to exist in the
mouse (see the following websites for details : http://www.
uta.¢/%7Eloiika/ADAMs/MMADAMs.htm, http://www.
people.Virginia.EDU/Vjag6n/Table_of_the_ADAMs.html).
Of these, 14 have a catalytic site consensus sequence
(HEXXH) in their metalloprotease domain, and are therefore
predicted to have catalytic activity. The remaining 10 ADAMs
do not possess a catalytic site consensus sequence in their
otherwise conserved metalloprotease-like domain, and are
therefore most likely not catalytically active.
Although 14 mouse ADAMs have a catalytic site, only a
few of these ADAMs or their human orthologues have been
shown to possess catalytic activity. The ¢rst reported assay for
catalytic activity of an ADAM was cleavage of myelin basic
protein (MBP) by ADAM10/MADM [4,5]. Subsequently,
ADAM10 has been shown to be able to cleave peptides cor-
responding to the cleavage sites of tumor necrosis factor
(TNF) K and APP [6,7]. The TNFK convertase/ADAM17
was ¢rst puri¢ed based on its ability to cleave TNFK [8,9]
and has since been shown to cleave a variety of other peptides
and protein substrates in vitro [10,11]. Recombinant ADAM9
cleaves the insulin B chain, a generic protease substrate, as
well as several peptides derived from known cleavage sites of
proteins that are shed from the plasma membrane [12]. Fi-
nally, catalytic activity of ADAM12 and ADAM19 has been
demonstrated through their ability to cleave and bind the
protease inhibitor K2 macroglobulin [13,14]. Here we use
MBP as a substrate to demonstrate that ADAM28 is catalyti-
cally active, and to evaluate some of the properties of catalyti-
cally active ADAM28. ADAM28 is highly expressed in the
epididymis and in lymphocytes [15^17], and establishing an
assay for its catalytic activity is an important ¢rst step to-
wards analyzing the potential function of ADAM28 in sperm
maturation and in host defense.
2. Materials and methods
2.1. Reagents
Restriction endonucleases, T4 DNA ligase and Taq DNA polymer-
ase were obtained from Roche Molecular Biochemicals. All reagents
were obtained from Sigma unless indicated otherwise. Tissue inhibi-
tors of metalloproteases (TIMPs) 1 and 2 were kindly provided by Dr.
Gill Murphy (University of East Anglia, UK).
2.2. Expression constructs and generation of stable CHO cell lines
PCR was used to generate constructs corresponding to bases 60^
2063 (EC-Fc) or 60^1292 (MP-Fc) of mouse ADAM28 with a 5P KpnI
site and a 3P BamHI site. ADAM28 in pBluescript or a mutant
ADAM28 (Glu343-Ala) were used as templates [15]. KpnI/BamHI-
digested fragments were ligated into a pcDNA3 expression vector in
frame with the cDNA for the human IgG-Fc domain [18]. All cDNA
clones were sequenced on both strands (The BioResource Center,
Cornell University, Ithaca, NY, USA). CHO cells (ATCC) were trans-
fected using Lipofectamine (Gibco Life Technology). Cells were al-
lowed to recover overnight and were then transferred into medium
containing 500 Wg/ml G418 (Life Technology). Medium was changed
every 2 days for approximately 8 days. Single colonies were selected
and expanded, and conditioned medium and cellular proteins were
examined for the presence of Fc fusion proteins by Western blot
analysis [18] using an anti-human IgG antibody (Promega).
2.3. Puri¢cation of secreted Fc-tagged fusion proteins and of ADAM10
Stably transfected CHO cell clones were grown in serum free OP-
TIMEM containing penicillin, streptomycin and glutamine for 4^5
days. Conditioned media from 30^40 150 mm plates were pooled.
Cells and debris were removed by centrifugation (8000 rpm, Sorvall
GS3 rotor, 15 min, 4‡C) followed by ¢ltration through a 0.2 WM ¢lter
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(Nalgene). Fc fusion proteins were captured on a 1 ml Hi-Trap rPro-
tein A column (Amersham Pharmacia Biotechnology), washed with
phosphate-bu¡ered saline containing 2 mM Zn2 and eluted using
0.1 M glycine pH 3.2. 500 Wl fractions were collected and immediately
neutralized using 2 M Tris^HCl pH 8. Fractions containing the de-
sired fusion protein were pooled. ADAM10 was puri¢ed from bovine
brain as described previously [4,5].
2.4. Protease assays
Commercially available MBP (Sigma) was puri¢ed by electroelution
from a 15% SDS^polyacrylamide gel (see [18] for a description of the
electroelution procedure) in order to remove contaminating degrada-
tion products. Puri¢ed Fc-tagged ADAM28 (1 Wg) was incubated with
2.7 Wg of puri¢ed MBP at 37‡C overnight in 0.1 mM Tris^HCl pH
7.4, 0.1 M glycine, 10 mM CaCl2, and the resulting degradation prod-
ucts were separated by SDS^PAGE and stained with Coomassie bril-
liant blue R250. For N-terminal amino acid sequence determination,
the digestion products were separated on a 15% Novex SDS^polyac-
rylamide gel, transferred to PVDF membrane, and analyzed by auto-
mated Edman degradation, using an Applied Biosystems 477A seque-
nator [19]. Cleavage of the insulin B chain was performed as described
previously [12].
Wild-type and mutant forms of recombinant human ADAM28
were assessed for their ability to cleave a range of synthetic peptide
substrates including MCA-Pro-Leu-Gly-Dap(Dnp)-Ala-Arg-NH2
(8.3 WM), MCA-Pro-Cha-Gly-Nva-His-Ala-Dpa-NH2 (8.3 WM),
MCA-Pro-Leu-Ala-Nva-Dpa-Ala-Arg-NH2 (5 WM) and 4P,5P-dimeth-
oxy£uoresceinyl-Ser-Pro-Leu-Ala-Gln-Ala-Val-Arg-Ser-Ser-Ser-Cys
(4-(3-succinimid-1-yl)) £uorescein-NH2 (10 WM). All substrates were
synthesized by Bachem. Full length recombinant human MMP13, 14
and 19 and TNFK convertase were used as standards. The MMPs
were cloned, expressed and puri¢ed essentially as described in [20^
22], while TNFK convertase was isolated from the membranes of
THP-1 cells as described in [23]. The enzymes were tested at starting
concentrations of 6 ng/assay (MMP14), 5.83 ng/assay (MMP13), 60
ng/assay (MMP19) and 0.0066 U/assay (TNFK convertase, where a
unit is the amount of enzyme needed to cleave 1 WM of substrate in
2 h). ADAM28 wild-type and mutants were tested from 1 to 10 Wl/
assay (stock concentrations were between 35 Wg/ml and 50 Wg/ml)
using. For all assays the bu¡er used was 0.1 M Tris^HCl pH 7.5,
0.1 M NaCl, 10 mM CaCl2, 0.05% (w/v) Brij 35 and 0.02 mM
ZnCl. Activity against the MCA containing synthetic substrates was
determined after incubation at 37‡C for 0.5, 1, 5.5 and s 72 h using
a Fluoroscan II (Labsystems) at settings Vex 328 nm, Vem 393 nm,
while activity against £uorescein containing substrate was determined
after incubation at 25‡C or 37‡C for 18 h at settings Vex 490 nm, Vem
530 nm.
3. Results and discussion
Three constructs for expression of ADAM28 fusion pro-
teins in CHO cells were generated. One consisted of the entire
ectodomain of ADAM28 including the EGF repeat fused to
the Fc domain of human IgG1 (Fig. 1A, EC-Fc). A second
consisted of the pro- and metalloprotease domains fused to
the Fc domain (Fig. 1A, MP-Fc). Finally, as a control, a
mutation that is known to abolish or greatly reduce the cata-
lytic activity of Zn-dependent metalloproteases was intro-
duced into the catalytic site of the EC-Fc construct (Fig.
1A, HEXXH-HAXXH, referred to as E343sA hereafter)
[12,24]. CHO cells stably expressing each construct were se-
lected, and the corresponding fusion proteins were isolated
from supernatants on protein A Sepharose beads (Fig.
1B,C). Puri¢ed ADAM28 EC-Fc had an apparent mass of
122 kDa on an SDS gel. The apparent mass of mature
ADAM28 MP-Fc was 85 kDa, whereas that of the less abun-
dant precursor form of ADAM28 MP-Fc was 102 kDa (Fig.
1B). ADAM28 EC-Fc E343sA had an apparent mass of 134
kDa and thus migrated slower than wild-type ADAM28 EC-
Fc (Fig. 1C), consistent with our previous observation that
pro-domain removal of ADAM28 depends on the presence of
the active site glutamate residue.
To test for catalytic activity of ADAM28, the puri¢ed Fc
fusion proteins were incubated with MBP, a substrate that has
previously been shown to be cleaved by ADAM10 (Fig. 2)
[4,5], and with the insulin B chain, which was previously
shown to be cleaved by ADAM9 and TNFK convertase.
ADAM28 was unable to cleave the insulin B chain protein
(data not shown). However, when MBP was incubated with
ADAM28 EC-Fc, two major cleavage products of around 4
and 6 kDa were generated. When an equal amount of
ADAM28 EC-Fc E343sA was incubated with MBP, no
cleavage products were seen. The catalytic activity did not
depend on the presence of the disintegrin domain, cysteine-
rich region and EGF repeat, as the MP-Fc construct gener-
ated cleavage products from MBP that co-migrated with those
generated by the EC-Fc fusion protein. These results provide
the ¢rst direct evidence for catalytic activity of ADAM28.
Fig. 1. Expression of ADAM28 EC-Fc and MP-Fc fusion proteins.
Panel A presents the domain organization of ADAM28, which is
also typical for other ADAMs, and a diagram of the ADAM28
EC-Fc and MP-Fc fusion proteins and of the wild-type and mutant
catalytic site of ADAM28. A comparison of puri¢ed ADAM28 EC-
Fc and MP-Fc is shown in B, and of the catalytic site mutant
ADAM28 EC-Fc and wild-type ADAM28 EC-Fc is shown in C. In
both B and C, the samples were separated by SDS^PAGE, and
stained with Coomassie brilliant blue.
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An unresolved question regarding the catalytic activity of
di¡erent ADAMs is whether these enzymes have similar or
distinct substrate speci¢cities and cleavage site preferences.
ADAM9 has previously been shown to have a di¡erent in
vitro cleavage speci¢city for peptide substrates compared to
ADAM17/TNFK convertase [12]. On the other hand, TNFK
convertase and ADAM10 cleave certain substrates at the same
site, such as peptides mimicking the cleavage site of TNFK
[6,8,9] and APP [7,25]. To address this issue, we compared the
MBP cleavage products produced by ADAM28 to those pro-
duced by ADAM10 (Fig. 2). Di¡erent-sized cleavage products
are generated when MBP is incubated with ADAM28 versus
ADAM10. Microsequencing of ADAM28 and ADAM10
cleavage products generated in a separate experiment never-
theless revealed two cleavage sites that are used by ADAM10
and ADAM28 (SLP72/QKA and ASA17/STM, see Fig. 3). In
addition, one cleavage site was only observed after cleavage
with ADAM28 (KGR107/GLS), and another only after cleav-
age with ADAM10 (HAA63/RTT). These ¢ndings suggest that
the cleavage site speci¢city of ADAM28 in vitro is similar, but
not identical to ADAM10.
In an attempt to identify other substrates of ADAM28,
wild-type and mutant forms of recombinant human
ADAM28 were assessed for their ability to cleave a range
of synthetic peptide substrates. No cleavage by wild-type or
mutant ADAM28 was detected using a general matrix metal-
loproteinase-like substrate (MCA-Pro-Leu-Gly-Dap(Dnp)-
Ala-Arg-NH2), a collagenase-like substrate (MCA-Pro-Cha-
Gly-Nva-His-Ala-Dpa-NH2), a stromelysin-like substrate
(MCA-Pro-Leu-Ala-Nva-Dpa-Ala-Arg-NH2) or a TNFK con-
vertase-like substrate (4P,5P-dimethoxy£uoresceinyl-Ser-Pro-
Leu-Ala-Gln-Ala-Val-Arg-Ser-Ser-Ser-Cys (4-(3-succinimid-1-
yl)) £uorescein-NH2) despite the standards being active in
these assays at concentrations of 6 2 ng/well (data not
shown). The results with the TNFK convertase-like substrate
further support the observation that ADAM28 has a di¡erent
cleavage site speci¢city than ADAM10 and ADAM17/TNFK
convertase.
ADAM28 is more closely related to soluble snake venom
metalloproteases than other ADAMs with a catalytic site.
Since snake venom metalloproteases are able to cleave a vari-
ety of extracellular matrix proteins, we tested whether
ADAM28 EC-Fc can cleave collagen types I, II, IV, and V,
laminin, or ¢bronectin. However, under conditions where
cleavage of MBP was readily observed, we did not detect
any cleavage of the matrix proteins tested here (data not
shown).
To further characterize the catalytic activity of ADAM28,
we assessed the e¡ects of known inhibitors of metallopro-
teases on MBP cleavage using ADAM28 EC-Fc (Fig. 4).
Identical results were obtained in a similar experiment using
ADAM28 MP-Fc instead of EC-Fc (data not shown). As
expected for a Zn2-dependent metalloprotease, ADAM28
cleavage of MBP can be inhibited by 5 mM EDTA, and by
1 mM of the Zn2 chelator 1:10 phenanthroline. TIMPs have
emerged as very useful tools for the characterization of metal-
loprotease activities in cells and in vitro [26^31]. Cleavage of
MBP by ADAM28 was not inhibited by 76 nM TIMP1, and
Fig. 2. Cleavage of MBP by ADAM28 EC-Fc, EC-Fc EsA, MP-
Fc, and ADAM10. Cleavage products generated by incubation of
di¡erent ADAM28 Fc fusion proteins or ADAM10 with bovine
MBP were separated by SDS^PAGE and stained with Coomassie
brilliant blue (A).
Fig. 3. Amino-terminal sequence of the MBP cleavage products gen-
erated by ADAM28 or ADAM10. The cleavage sites for ADAM28
EC-Fc, ADAM28 MP-Fc, and ADAM10 are shown in the table
(upper panel) and are highlighted in bold font in the complete se-
quence of bovine MBP (lower panel, GenBank accession number
P02687).
Fig. 4. Evaluation of the e¡ect of inhibitors of metalloproteases on
MBP cleavage by ADAM28 EC-Fc. ADAM28 EC-Fc and MBP
were co-incubated in the presence of known inhibitors of metallo-
proteases, or in the appropriate control bu¡ers. The ¢rst two lanes
show either ADAM28 EC-Fc or MBP incubated under identical
conditions.
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by up to 178 nM TIMP2. Thus, ADAM28 is not inhibited by
TIMPs 1 and 2 at concentrations which potently inhibit
known matrix metalloproteases [32]. In this respect,
ADAM28 resembles ADAM17/TNFK convertase and
ADAM19 [14,28]. In contrast, ADAM10/KUZ is inhibited
by TIMP1, but not by TIMP2 [27]. ADAM17/TNFK conver-
tase, ADAM10/KUZ, and ADAM12 are also inhibited by
TIMP3 [27,28,30]. In this study we were unable to obtain
su⁄cient quantities of TIMP3 to test the sensitivity of
ADAM28 to this inhibitor.
In a previous study, we found that ADAM28 pro-domain
removal can be abolished by the E343sA mutation ([15], see
also Fig. 1C). This suggests that ADAM28 pro-domain re-
moval is, at least in part, autocatalytic. In contrast, the pro-
domains of most catalytically active ADAMs are apparently
removed by furin or a related pro-protein convertase
[12,18,33,34]. In order to identify the sites of ADAM28 pro-
domain cleavage, we subjected the EC-Fc and MP-Fc fusion
proteins to N-terminal sequencing. This revealed four cleav-
age sites which were identical for both fusion proteins (see
Fig. 5). One of the cleavage sites (VSA20/IKE) is the predicted
signal sequence cleavage site [15], whereas the other three are
in the pro-domain of ADAM28. This suggests that ADAM28
pro-domain removal involves several steps. In comparison,
the pro-domains of ADAM15 and ADAM17 are also cleaved
at least three times after processing by a pro-protein conver-
tase [18,35]. The pro-domains of all ADAMs with a catalytic
site consensus sequence contain an additional cysteine residue
that is thought to inhibit the protease via a cysteine switch
mechanism (see for example [12,18,34]). Evidently the pro-
domain of ADAM28 does not prevent the autocatalytic pro-
domain cleavage, although it is not clear whether the pro-
domain must be removed for ADAM28 to be able to cleave
other proteins.
Taken together, these studies provide the ¢rst direct evi-
dence for catalytic activity of ADAM28. The ¢nding that
ADAM28 is catalytically active in vitro further supports the
notion that the catalytic activity of this molecule will be rel-
evant for its function in vivo. The relatively high expression of
ADAM28 in the epididymis and in lymphocytes suggests a
role for this ADAM in sperm maturation and in lymphocyte
function. Further studies, including a targeted deletion of
ADAM28 in mice, will be required to learn more about the
physiological role of this protein in reproduction, develop-
ment, host defense, and in adult homeostasis.
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